通化东宝（600867）公告，公司董事会通过协议转让特宝生物部分股份的议案。通化东宝拟以协议转让 方式向西藏信托有限公司转让特宝生物无限售条件流通股2318.76万股，占特宝生物当前总股本的 5.7%。转让价格为每股56.12元，总价款为人民币13.01亿。本次交易未构成关联交易及重大资产重组， 尚需提交股东会审议。本次协议转让旨在推动企业向创新型药企转型。 ...

为出具本法律意见书，本所指派郭淑芬、裴昕桐律师出席了公司于 2025 年 开本次股东大会有关的文件和资料，并进行了验证。在此基础上，本所按照律师 行业公认的业务标准、道德规范和勤勉尽责的精神发表法律意见如下： 公司董事会已于 2025 年 4 月 30 日在《中国证券报》《上海证券报》及上海 证券交易所网站（http://www.sse.com.cn/）上刊登了《通化东宝药业股份有限 公司关于召开 2024 年年度股东大会的通知》（以下简称"通知"）。在此通知 中载明了召开 2024 年年度股东大会的时间、地点、内容、出席会议人员的资格 和出席会议的登记办法，并说明了有权出席会议股东的股权登记日及其委托代理 人出席会议并参加表决的权利。 一、公司本次股东大会的召集和召开程序 本次股东大会由公司董事会召集，会议召开方式为现场投票与网络投票相结 合的方式。 致：通化东宝药业股份有限公司 根据《中华人民共和国证券法》（以下简称"证券法"）、《中华人民共 和国公司法》（以下简称《公司法》）、《上市公司股东会规则》（以下简称《股 东会规则》）和《通化东宝药业股份有限公司章程》（以下简称《公司章程》） 的有关规定，吉林秉 ...

业集团股份有限公司及相关联股东回避了表决。 | 证券代码：600867 证券简称：通化东宝 | | | | | | 公告编号：2025-035 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 通化东宝药业股份有限公司 | | | | | | | | | | | | 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 | | | | | | | | | | | | 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 | | | | | | | | | | | | 重要内容提示： | | | | | | | | | | | | ? 本次会议是否有否决议案：无 | | | | | | | | | | | | 一、 会议召开和出席情况 | | | | | | | | | | | | (一)股东大会召开的时间：2025 日 | | 年 5 月 | 21 | | | | | | | | | (二)股东大会召开的地点：公司会议室 | | | | | | | | | | | | (三)出 ...

证券代码：600867 证券简称：通化东宝 公告编号：2025-035 通化东宝药业股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一)股东大会召开的时间：2025 年 5 月 21 日 (二)股东大会召开的地点：公司会议室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 560 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 838,757,935 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 43.1579 | (四)表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 表决情况： | 股东类型 | 同意 | | 反对 | | 弃权 | | | --- | --- | --- | --- | --- | --- | --- | | | 票数 | ...

吉林秉责律师事务所 关于通化东宝药业股份有限公司 二 0 二四年年度股东大会的法律意见书 网络投票时间：网络投票起止时间：自 2025 年 5 月 21 日 至 2025 年 5 月 21 日。采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间 为股东大会召开当日的交易时间段，即 9:15-9:25,9:30-11:30，13:00-15:00；通过 互联网投票平台的投票时间为股东大会召开当日的 9:15-15:00。 经本所律师审查，公司本次股东大会召开的时间、地点符合公告通知的内容。 公司本次股东大会召集、召开的程序符合《公司法》、《证券法》、《股东会规 则》、《上海证券交易所上市公司股东大会网络投票实施细则》等有关法律、法 规、规范性文件和《公司章程》的有关规定。 致：通化东宝药业股份有限公司 根据《中华人民共和国证券法》（以下简称"证券法"）、《中华人民共 和国公司法》（以下简称《公司法》）、《上市公司股东会规则》（以下简称《股 东会规则》）和《通化东宝药业股份有限公司章程》（以下简称《公司章程》） 的有关规定，吉林秉责律师事务所（以下简称"本所"）接受了通化东宝药业股 份有限公司（以下简 ...

证券代码：600867 证券简称：通化东宝 公告编号：2025-034 通化东宝药业股份有限公司 关于 2024 年度和 2025 年第一季度业绩说明会 变更会议召开信息的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ? 会议召开时间：2025 年 5 月 27 日（星期二） 15:00-16:30 ? 会议召开地点：全景网"投资者关系互动平台"（网址： https://rs.p5w.net/c/600867） ? 会议召开方式：网络在线问答互动 公司将召开 2024 年度和 2025 年第一季度业绩说明会暨参加由吉林省证券业 协会、深圳市全景网络有限公司共同举办的"2025 年吉林辖区上市公司投资者 网上集体接待日活动"，本次投资者说明会以网络互动形式召开，公司将针对 展战略、经营状况等与投资者进行互动交流和沟通，在信息披露允许的范围内就 投资者普遍关注的问题进行回答。 二、说明会召开的时间、地点 （一）会议召开时间：2025 年 5 月 27 日 15:00-16:30 （二）会议召开地点：全景网" ...

证券代码：600867 证券简称：通化东宝 公告编号：2025-034 通化东宝药业股份有限公司 关于 2024 年度和 2025 年第一季度业绩说明会 变更会议召开信息的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2025 年 5 月 27 日（星期二） 15:00-16:30 会 议 召 开 地 点 ： 全 景 网 " 投 资 者 关 系 互 动 平 台 " （ 网 址 ： https://rs.p5w.net/c/600867） （三）会议召开方式：网络在线问答互动 三、参加人员 会议召开方式：网络在线问答互动 通化东宝药业股份有限公司（以下简称"公司"）已于 2025 年 4 月 30 日 在上海证券交易所网站（www.sse.com.cn）披露了《通化东宝关于召开 2024 年 度和 2025 年第一季度业绩说明会的公告》（公告编号：2025-030）。因相关工 作时间安排，现变更本次业绩说明会的召开时间、地点等信息，时间由 2025 年 5 月 26 日变更为 2025 年 ...

61只个股今日获机构买入型评级，电连技术最新评级被调高，12股机构首次关注。 证券时报·数据宝统计显示，今日机构研报共发布62条买入型评级记录，共涉及61只个股。赛轮轮胎关 注度最高，共获2次机构买入型评级记录。 今日获机构买入型评级个股中，共有13条评级记录中对相关个股给出了未来目标价。以公布的预测目标 价与最新收盘价进行对比显示，共有11股上涨空间超20%，北新建材上涨空间最高，5月15日国泰海通 预计公司目标价为49.00元，上涨空间达69.96%，上涨空间较高的个股还有长城汽车、通化东宝等，上 涨空间分别为68.46%、45.66%。 机构今日买入型评级个股 | 代码 | 简称 | 买入评级家数 | 今日涨跌幅（%） | 动态市盈率（倍） | 行业 | | --- | --- | --- | --- | --- | --- | | 601058 | 赛轮轮胎 | 2 | -1.55 | 10.05 | 汽车 | | 601633 | 长城汽车 | 1 | -0.42 | 28.79 | 汽车 | | 603297 | 永新光学 | 1 | -1.97 | 43.04 | 电子 | | 603368 | ...

Group 1 - Tonghua Dongbao has received approval from Nicaragua's National Health Regulatory Authority for its recombinant human insulin injection, which is expected to enhance the company's international market presence and brand image [1] - The diabetes patient population in Nicaragua is projected to reach 377,000 by 2024, with an 8.7% prevalence rate among adults aged 20-79, indicating a significant market opportunity for the company [1] - The average annual expenditure per diabetes patient in Nicaragua is estimated at $587, highlighting the potential revenue generation from the new product [1] Group 2 - Haobor's response to the 2024 annual report inquiry reflects the company's commitment to regulatory compliance and transparency, addressing concerns regarding its distribution model and dealer management [2] - The detailed analysis of dealer numbers and management policies demonstrates the stability and rationality of the company's business model, which may alleviate investor concerns [2] - Continuous optimization of dealer management is expected to provide strong support for the company's long-term development [2] Group 3 - Kangji Medical has decided to terminate the sale of a subsidiary and has reached a settlement agreement with the buyer, which includes the return of company records and a refund of 5 million yuan [3] - The company expects to realize approximately 39.3 million yuan in gains from a land recovery agreement with government agencies, indicating effective management of complex transactions [3] - The resolution of this transaction is likely to stabilize investor confidence and positively impact the company's long-term growth prospects [3] Group 4 - Jincheng Pharmaceutical has signed a licensing and distribution agreement with UK-based Theramex HQ UK Limited for the hormone replacement therapy product Bijuva, aimed at addressing estrogen deficiency symptoms in postmenopausal women [4] - This collaboration aligns with the company's strategy to enhance its offerings in women's health and strengthen partnerships with international pharmaceutical firms [4] - The agreement is expected to expand the company's product portfolio in the women's health sector and improve its brand influence in this market [4]

Group 1 - Shengyi Electronics plans to repurchase shares with a total amount between 50 million and 100 million yuan, at a price not exceeding 43.02 yuan per share, for employee stock ownership plans [1] - Guoyao Modern's subsidiary has passed the consistency evaluation for the quality and efficacy of a generic drug, which is used for treating severe infections [1] - Tianhe Magnetic Materials' subsidiaries have obtained project filing notices for high-performance rare earth permanent magnet projects, with total investments of 100 million yuan and 50 million yuan respectively [1][2] Group 2 - Dream Lily intends to repurchase shares with an amount between 85 million and 170 million yuan, at a price not exceeding 10.90 yuan per share, supported by a loan commitment of up to 150 million yuan [3] - Weifu High-Tech has received a loan commitment of up to 135 million yuan from a financial institution for share repurchase [3] Group 3 - Lu'an Environmental Energy reported a coal sales volume of 4.51 million tons in April, a year-on-year increase of 17.75% [5] - *ST Tianshan reported a significant decline in livestock sales and revenue, with a revenue of 70,500 yuan in April, down 95.68% year-on-year [7] Group 4 - Feirongda announced a cash dividend of 0.38 yuan per 10 shares, with a total distribution of 21.9 million yuan [8] - Zhejiang Rongtai's shareholders and executives plan to reduce their holdings by up to 1.93% of the company's shares [9] Group 5 - Changhua Group's subsidiary won the land use rights for an industrial site in Ningbo for 27.05 million yuan, intended for manufacturing and related business [11] - Zejing Pharmaceutical's new drug application for a treatment for severe alopecia has been accepted by the regulatory authority [13][14] Group 6 - Hainan Mining plans to distribute a cash dividend of 0.8 yuan per 10 shares, totaling 1.59 billion yuan [15] - China Jushi plans to distribute a cash dividend of 0.24 yuan per share, totaling 9.61 billion yuan [16] Group 7 - Zhengzhong Design's subsidiary has obtained a utility model patent for an acrylic signage guide [18] - Rundu Co., Ltd. received approval for a veterinary drug product, which is intended for treating bacterial diseases in livestock [20] Group 8 - Emei Mountain A announced the resignation of its general manager due to work reasons [22] - Tonghua Dongbao's insulin injection has received a registration certificate in Nicaragua, allowing for sales in that market [23] Group 9 - Dizu Fashion's subsidiary has completed the registration of a private equity investment fund [24] - Ningbo Gaofa plans to increase capital by 60 million yuan in its subsidiary for operational needs [26] Group 10 - Haichuan Intelligent has obtained two utility model patents for material handling devices [27] - Newland's subsidiary signed a deep cooperation agreement with Alibaba Cloud for AI model applications [29] Group 11 - Rui Neng Technology's controlling shareholder plans to reduce its stake by up to 2.89% [30] - Guomai Culture intends to repurchase shares between 50 million and 100 million yuan for capital reduction [31] Group 12 - Shaanxi Construction won major construction projects totaling 7.88 billion yuan in April [32] - Hanyu Pharmaceutical signed a joint development agreement for a new peptide drug with a partner [34] Group 13 - Yunnan Copper is planning to acquire a 40% stake in Liangshan Mining, leading to a stock suspension [35] - Haizheng Pharmaceutical plans to repurchase shares between 50 million and 100 million yuan for employee stock ownership [36] Group 14 - Tianqiao Hoisting's controlling shareholder plans to increase its stake by 75 million to 150 million yuan [37] - Tiandi Online's controlling shareholder is transferring shares to introduce a strategic investor [38] Group 15 - Hongchang Technology plans to invest 15 million yuan in a joint venture with a partner [39] - Rabbit Baby's subsidiary is preparing for an IPO in Hong Kong [41] Group 16 - Wol Nuclear Materials is planning to issue H-shares for listing in Hong Kong [42] - Tangyuan Electric plans to raise up to 864 million yuan through a private placement for various projects [43] Group 17 - Tongrun Equipment's major shareholders plan to reduce their holdings by up to 2% [44] - Linzhou Heavy Machinery plans to raise up to 600 million yuan through a private placement [46] Group 18 - China Merchants Securities announced the resignation of its vice president [47] - Shangsheng Electronics plans to issue convertible bonds to raise up to 330 million yuan for various projects [48] Group 19 - Longda Co., Ltd.'s major shareholder plans to reduce its stake by up to 1% [49] - China Medical plans to acquire 100% of Jinsui Technology for 302 million yuan [50] Group 20 - Silek has signed a strategic cooperation agreement with a battery manufacturer [51] - Boyun New Materials' major shareholder plans to reduce its stake by up to 3% [53]